Ovarian steroid cell tumor (not otherwise specified) with subsequent spontaneous pregnancy after tumor removal: a case report and literature review

Matemanosak, Phawat; Peeyananjarassri, Krantarat; Suwanrath, Chitkasaem; Wattanakumtornkul, Saranya; Klangsin, Satit; Thiangphak, Ekasak; Kanjanapradit, Kanet

doi:10.1080/09513590.2023.2186138

Cited by 4 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In benign cases, the serum testosterone level generally normalizes within days or weeks following surgical resection of SCT ( 16 ). Successful pregnancy is achievable following surgery, usually within 1 year of tumor removal ( 53 , 54 ). Virilization and hirsutism are usually resolved within a year of surgical tumor removal.…”

Section: Patient Outcomes and Possible Pathologic Predictorsmentioning

confidence: 99%

Ovarian steroid cell tumors: what do we know so far?

Wei,

Fadare

2024

Front. Oncol.

View full text Add to dashboard Cite

Steroid cell tumors (SCT) of the ovary are rare, which has limited advances in the understanding of this enigmatic neoplasm. In this review, we summarize currently known clinicopathologic information on SCT. SCT are frequently hormonally active, leading to elevated serum and/or urine levels of androgenic hormones or their metabolites, and associated symptomatology, including virilization. The reported age at diagnosis is broad and has ranged from as young as 1 year old to 93 years old, although most patients were between ages 20 and 40 years. Most tumors are stage I and unilateral. The tumors are usually well circumscribed with a solid or solid to cystic cut surface. The tumors in one series reportedly ranged in size from 1.2 to 45 cm (average 8.4 cm). MRI is a useful imaging modality, typically showing a well delineated mass with contrast enhancement and lipid content on T2 and T1 weighted images, respectively. Microscopically, SCT display polygonal to epithelioid cells with abundant eosinophilic to vacuolated/clear cytoplasm and display an immunoprofile that is consistent with sex cord-stromal differentiation. Most cases are benign, without any recurrences after primary resection, but a subset – probably less than 20% of cases –are clinically malignant. Pathologic criteria that can specifically predict patient outcomes remain elusive, although features that correlate with adverse outcomes have been proposed based on retrospective studies. The molecular characteristics of SCTs are similarly under characterized, although there is some evidence of an enrichment for hypoxia-signaling gene mutations in SCT. In malignant SCT, the tumors generally show greater global genomic instability, copy number gains in oncogenes, and occasional BAP1 mutation. Future studies involving multi-institutional cohort and unbiased molecular profiling using whole exome/transcriptome sequencing are needed to help advance our molecular understanding of SCTs.

show abstract

Section: Patient Outcomes and Possible Pathologic Predictorsmentioning

confidence: 99%

Ovarian steroid cell tumors: what do we know so far?

Wei,

Fadare

2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

Ovarian steroid cell tumour, not otherwise specified: A case report

Yue

Aziz

Wang

et al. 2023

European Journal of Obstetrics & Gynecology and Reproductiv

View full text Add to dashboard Cite

Ovarian steroid cell tumors, not otherwise specified: three case reports and literature review

Sun,

Tian,

Meng

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveTo provide a reference for the diagnosis and treatment of ovarian steroid cell tumors, not otherwise specified (SCTs-NOS).MethodsWe retrospectively analyzed the clinicopathological data of three patients with SCTs-NOS admitted to the Tianjin Medical University General Hospital from 2012 to 2022 and reviewed literature reports related to this disease.ResultsA total of 3 cases in our center and 70 cases searched in literature reports were included. The age at diagnosis ranged from 3 to 93 years (median, 34 years). The common clinical manifestations were hirsutism, acne, deepened voice, clitoromegaly, amenorrhea, and excessive weight gain. Tumor sizes ranged from 1.2 to 45 cm, with an average diameter of 6.5cm. Most of SCTs-NOS were benign, but some of them exhibited malignant behavior. Surgery was the main treatment and close follow-up was required. The follow up time of 73 cases ranged from 3 to 132 months (median, 21.3 months). Disease recurrence or progression occurred in 14 cases (19.2%). Three of the 73 patients had a successful pregnancy.ConclusionSCTs-NOS usually occur in women of reproductive age, which are mainly manifested as androgen excess symptoms. Surgery is an appropriate treatment for SCTs-NOS and should be individualized. Final diagnosis depends on pathology. SCTs-NOS have malignant potential, and the treatments for patients with malignant tumors and disease recurrence or progression were cytoreductive surgery, adjuvant chemotherapy, and gonadotrophin-releasing hormone agonists (GnRHa) therapy.

show abstract

Ovarian steroid cell tumor (not otherwise specified) with subsequent spontaneous pregnancy after tumor removal: a case report and literature review

Cited by 4 publications

References 11 publications

Ovarian steroid cell tumors: what do we know so far?

Ovarian steroid cell tumors: what do we know so far?

Ovarian steroid cell tumour, not otherwise specified: A case report

Ovarian steroid cell tumors, not otherwise specified: three case reports and literature review

Contact Info

Product

Resources

About